LSV Asset Management reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,649,037 shares of the biopharmaceutical company’s stock after selling 65,866 shares during the period. LSV Asset Management’s holdings in Gilead Sciences were worth $290,797,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. Advisors Preferred LLC acquired a new position in Gilead Sciences in the 4th quarter valued at about $31,000. Legacy Financial Advisors Inc. grew its position in Gilead Sciences by 361.3% in the 4th quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 383 shares in the last quarter. We Are One Seven LLC acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $37,000. Jackson Grant Investment Advisers Inc. grew its position in shares of Gilead Sciences by 56.9% during the fourth quarter. Jackson Grant Investment Advisers Inc. now owns 717 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 260 shares in the last quarter. Finally, Baldwin Brothers Inc. MA grew its position in shares of Gilead Sciences by 47.2% during the fourth quarter. Baldwin Brothers Inc. MA now owns 808 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 259 shares in the last quarter. Hedge funds and other institutional investors own 77.76% of the company’s stock.
GILD stock opened at $66.98 on Thursday. The company has a market cap of $86.36 billion, a P/E ratio of 10.89, a price-to-earnings-growth ratio of 4.20 and a beta of 1.19. Gilead Sciences, Inc. has a fifty-two week low of $60.32 and a fifty-two week high of $82.71. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.36 and a quick ratio of 3.29.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing the consensus estimate of $1.70 by ($0.26). The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.52 billion. Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. Gilead Sciences’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.78 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 6.23 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 28th. Investors of record on Friday, March 15th will be paid a dividend of $0.63 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.57. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $2.52 annualized dividend and a yield of 3.76%. Gilead Sciences’s payout ratio is presently 37.07%.
In other Gilead Sciences news, Director Gayle E. Wilson sold 19,068 shares of the business’s stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $67.08, for a total value of $1,279,081.44. Following the completion of the sale, the director now owns 143,567 shares in the company, valued at $9,630,474.36. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director John C. Martin sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $71.20, for a total value of $3,560,000.00. Following the completion of the sale, the director now owns 2,877,762 shares of the company’s stock, valued at approximately $204,896,654.40. The disclosure for this sale can be found here. 1.16% of the stock is owned by insiders.
A number of equities analysts have recently commented on the company. ValuEngine raised Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, December 1st. Zacks Investment Research downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, January 23rd. Citigroup reissued a “buy” rating and set a $100.00 price objective on shares of Gilead Sciences in a research report on Tuesday, February 5th. Mizuho set a $94.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Thursday, November 1st. Finally, CIBC raised Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 price objective for the company in a research report on Thursday, January 3rd. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and an average target price of $83.59.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Macon Daily and is the sole property of of Macon Daily. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://macondaily.com/2019/02/21/gilead-sciences-inc-gild-shares-sold-by-lsv-asset-management.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Recommended Story: Closed-End Mutual Funds (CEFs)
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.